Epithelial Defect and Corneal Haze

Breakthrough stem cell therapy repairs cornea damage

New stem cell therapy could repair 'irreversible' and blinding eye damage, trial finds

A new stem cell therapy has repaired blinding damage to the cornea in 93% of patients in an early clinical trial. The cornea is the clear dome that covers the front of the eye and helps to focus light to enable you to see clearly.

Medical Xpress on MSN · 2d

Novel stem cell therapy repairs 'irreversible' corneal damage in clinical trial

An expanded clinical trial that tested an experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients who were treated and followed for 18 months,

UPI News on MSN · 18h

Breakthrough stem cell therapy repairs cornea damage once deemed untreatable

Sight-robbing injuries to the cornea can be repaired using a groundbreaking experimental stem cell treatment, a new study shows. The cornea -- the clear outermost layer of the eye -- can become irreve

Gizmodo · 1d

Groundbreaking Stem Cell Therapy Repairs Badly Damaged Corneas and Improves Sight

In most cases, the therapy—a transplant of stem cells from the person’s other healthy eye—appeared to safely restore the surface of people’s severely damaged corneas, often improving their vision as well.

Medical News Today · 1d

Stem cell therapy could heal injured corneas, restore vision

An experimental stem cell therapy reversed corneal damage in half of the participants from a recent clinical trial.

Ophthalmology Times9d

Gaining control of persistent corneal epithelial defects using AMT and a pressure patch

Combining eyelid pressure patching with AMT effectively heals persistent corneal epithelial defects, offering rapid ...

News Medical on MSN5d

Advances in corneal healing research drive new treatments for rare eye diseases

Rare eye diseases are the leading cause of untreatable blindness in Europe and affect people of all ages. The RESTORE VISION ...

Medscape3d

Ocular Surface Reconstruction: Recent Innovations, Surgical Candidate Selection and Postoperative Management

Patients with limbal deficiency may benefit from limbal stem cell transplantation to alleviate persistent epithelial defects, maintain conjunctivalization regression and corneal avascularity ...

Ophthalmology Times9d

FDA accepts NDA for epi-on corneal crosslinking Epoxia from Glaukos

A PDUFA date has been set for October 20, 2025. If approved, Epoxia will be the first epi-on corneal crosslinking on the market.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results